Purdue Pharma L.P.

Purdue Pharma L.P. | February 07, 2017

Purdue Pharma L.P. today announced the appointment of Margaret K. Feltz, Esq. to Vice President and Chief Ethics & Compliance Officer, reporting to President and Chief Executive Officer Mark Timney. Feltz succeeds Bert Weinstein, Esq., who retired from Purdue Pharma in December 2016....

Purdue Pharma L.P. | February 23, 2017

Purdue Pharma L.P. today announced the promotion of Maria A. Barton, Esq., Vice President, from Deputy General Counsel to General Counsel. Barton will become a member of the Executive Committee and will report to Purdue Pharma President and Chief Executive Officer Mark Timney, effective immediately....

Purdue Pharma L.P. | March 23, 2017

Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Symproic® (naldemedine) 0.2 mg tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain....

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...